Facio plans to select first series of potential drug development candidates early 2018


Leiden, the Netherlands - December 20, 2017

Facio Therapies announced today that early 2018 it plans to select a first series of potential FSHD drug development candidates comprising DUX-4 repressing small-molecule compounds that leave muscle cell formation intact. Facio also announced that BET inhibitors and beta-2 adrenergic receptor (b-2AR) agonists, two compound classes that have been linked to FSHD in the scientific… read more

Facio builds innovative portfolio of potential drug development candidates


Leiden, the Netherlands - November 9, 2017

Facio Therapies announced today that it is building a portfolio of potential FSHD drug development candidates comprising small-molecule compounds that repress the production of the muscle-toxic protein, DUX4, while leaving muscle cell formation intact. Never before have any of these compounds been linked to FSHD in the scientific literature. Undue production of DUX4 in skeletal… read more

Facio to present at World Orphan Drug Congress


Leiden, the Netherlands - November 3, 2017

Facio Therapies announced today that its managing director, David Dasberg, has been invited to speak at the 8th World Orphan Drug Congress (WODC), which will be held in Barcelona on 13-15 November 2017. Undue production of DUX4 in skeletal muscle is the cause of FSHD. DUX4 sets in motion a cascade of biochemical events that eventually result… read more

Facio names US ambassador


Leiden, the Netherlands - September 8, 2017

Facio Therapies announced today that Jennifer Burgess has agreed to become Facio’s ambassador to the FSHD community in the USA. Ms Burgess will raise awareness of Facio’s mission and progress among American FSHD-affected families, their friends and healthcare impact investors.  Jennifer Burgess, Esq. is an independent attorney based in New York. She is the founder… read more

Facio expands Board


Leiden, the Netherlands - June 30, 2017

Facio Therapies announced today that Cord Dohrmann, David Mackay, and Chip Wilson have joined its Board.  Facio’s Board was expanded in conjunction with the successful raise of €4.8M in equity that Facio announced on 20 June, 2017. Cord Dohrmann is the Chief Scientific Officer and a member of the Management Board of Evotec, Facio’s strategic drug… read more

Facio raises €4.8M from the FSHD community and Evotec


Leiden, the Netherlands - June 20, 2017

Facio Therapies announced today that it had raised €4.8M (approximately A$7.1M or US$5.4M) in equity financing from a global investor syndicate composed of FSHD-affected families from Australia, Europe, and North America; the French patient organization, Amis FSH; and Facio’s drug discovery partner, German-based Evotec. Facio will use the proceeds of this funding to further accelerate… read more

Facio presents at AMIS FSH patient meeting


Leiden, the Netherlands - May 5, 2017

Facio Therapies is invited to present at the AMIS FSH patient meeting in Paris, France on May 13th, 2017. AMIS FSH is the French FSHD patient organization and also a member of the European consortium FSHD Europe. The AMIS FSH spring meeting discusses worldwide FSHD research and the opportunity it provides for potential treatments. Facio’s Managing Director,… read more

Facio presents at the 6th annual Orphan Drugs and Rare Diseases Europe Conference


Leiden, the Netherlands -

Facio Therapies will present its mission to improve the lives of people with FSHD, and showcase the latest results from its FSHD drug discovery program at the 6th annual Orphan Drugs and Rare Diseases Europe Conference in Berlin, Germany, on May 15th, 2017.   The 6th annual Orphan Drugs and Rare Diseases Europe Conference, is organized by… read more

FSHD Unlimited publishes 2016 Annual Report


Leiden, the Netherlands -

Facio provides updates on operational progress and financial results Facio Therapies announced today that its parent company, FSHD Unlimited, published its audited Annual Report for the year 2016. Having raised €875,000 in equity, the Facio group of companies ended the report period with €1.1M in cash and cash equivalents. Expenses were mainly directed at Facio’s… read more

Facio validates over 300 compounds with the potential to tackle the cause of FSHD


Leiden, the Netherlands - April 3, 2017

Facio Therapies announced today that it has validated more than 300 compounds (so-called “hits”) that repress the production of the muscle-toxic DUX4 protein in cultured muscle cells derived from FSHD patient biopsies. Undue production of DUX4 in skeletal muscle is the cause of FSHD. When produced in muscle tissue, DUX4 is highly toxic due to… read more